<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"> <channel>  <title><![CDATA[Clayton Utz | Pharmaceutical and Medical Devices - Publications]]></title>  <link>http://www.claytonutz.com/area_of_law/litigation_and_dispute_resolution/pharmaceutical_and_medical_devices/publications.page</link>  <description/>  <copyright><![CDATA[(c) Clayton Utz 2009]]></copyright>  <image>   <title><![CDATA[Clayton Utz]]></title>   <link>http://www.claytonutz.com/</link>   <url>http://www.claytonutz.com/images/logo.png</url>  </image>  <language>en-au</language> <item><guid>http://www.claytonutz.com/publications/news/201005/26/implementing_the_trips_protocol-public_comment_sought.page</guid><title><![CDATA[Implementing the TRIPS Protocol - public comment sought]]></title><link>http://www.claytonutz.com/publications/news/201005/26/implementing_the_trips_protocol-public_comment_sought.page</link><description><![CDATA[IPAustralia is seeking comment on the implementation of the TRIPS Protocol, which would make compulsory licences for pharmaceutical products easier to grant.]]></description><pubDate>Wed, 26 May 2010 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20090930/home.page</guid><title><![CDATA[Pharmaceutical Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20090930/home.page</link><description><![CDATA[This issue includes: One for all, and all for one? A unified approach to therapeutic goods promotion; There was movement at the station: the Australian consumer law reforms are being enacted into law; Regulatory reform: In brief; What's up doc? The doctor's duty of care to third parties; European developments: to regulate or not to regulate - that is the question?;]]></description><pubDate>Wed, 30 Sep 2009 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/docs/TheInternationalComparativeLegalGuideto_PharmaceuticalAdvertising2009.pdf</guid><title><![CDATA[International Comparative Legal Guide to Pharmaceutical Advertising 2009: Australia]]></title><link>http://www.claytonutz.com/docs/TheInternationalComparativeLegalGuideto_PharmaceuticalAdvertising2009.pdf</link><description><![CDATA[Colin Loveday and Greg Williams explain the basics of Australian pharmaceutical advertising law in this chapter excerpted from Global Legal Group's International Comparative Legal Guide to Pharmaceutical Advertising 2009.]]></description><pubDate>Thu, 02 Jul 2009 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20081202/home.page</guid><title><![CDATA[Pharmaceutical Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20081202/home.page</link><description><![CDATA[This issue includes: Product liability and class actions: Pharma and medical devices in the litigation league table; Regulation and reputation: The legal pitfalls; Cost recovery arrangements for PBS-listed medicines and vaccines;]]></description><pubDate>Tue, 02 Dec 2008 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/docs/TheInternationalComparativeLegalGuideto_PharmaceuticalAdvertising2008.pdf</guid><title><![CDATA[International Comparative Legal Guide to Pharmaceutical Advertising 2008: Australia]]></title><link>http://www.claytonutz.com/docs/TheInternationalComparativeLegalGuideto_PharmaceuticalAdvertising2008.pdf</link><description><![CDATA[Colin Loveday and Greg Williams explain the basics of Australian pharmaceutical advertising law in this chapter excerpted from Global Legal Group's International Comparative Legal Guide to Pharmaceutical Advertising 2008.]]></description><pubDate>Thu, 10 Jul 2008 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20080424/home.page</guid><title><![CDATA[Pharmaceutical Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20080424/home.page</link><description><![CDATA[This issue includes: Educator or promoter - Are you at risk of an identity crisis?; Increased transparency for corporate sponsorship of doctors' education; Is a unified consumer law in sight?; Developments in EU and UK consumer protection: a class act?; Pharmaceutical patent infringement - interlocutory injunctions now easier to obtain;]]></description><pubDate>Thu, 24 Apr 2008 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200708/31/if_you_deal_with_the_government_does_the_tpa_apply_to_you.page</guid><title><![CDATA[If you deal with the Government, does the TPA apply to you?]]></title><link>http://www.claytonutz.com/publications/news/200708/31/if_you_deal_with_the_government_does_the_tpa_apply_to_you.page</link><description><![CDATA[If Government is not "carrying on a business", it's not bound by the Trade Practices Act. Does that immunity generally extend to anyone negotiating or contracting with it? The High Court has said "no" in its decision in ACCC v Baxter [2007] HCA 38 (29 August 2007) reversing the effect of the decisions of the Federal Court and of the Full Court of the Federal Court on appeal.]]></description><pubDate>Fri, 31 Aug 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/docs/TheInternationalComparativeLegalGuideto_PharmaceuticalAdvertising2007-4thEdition.pdf</guid><title><![CDATA[International Comparative Legal Guide to Pharmaceutical Advertising 2007: Australia]]></title><link>http://www.claytonutz.com/docs/TheInternationalComparativeLegalGuideto_PharmaceuticalAdvertising2007-4thEdition.pdf</link><description><![CDATA[Colin Loveday and Greg Williams explain the basics of Australian pharmaceutical advertising law in this chapter excerpted from Global Legal Group's International Comparative Legal Guide to Pharmaceutical Advertising 2007.]]></description><pubDate>Mon, 13 Aug 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20070813/home.page</guid><title><![CDATA[Pharmaceutical Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20070813/home.page</link><description><![CDATA[This issue includes: ANZTPA abandoned for now; The future with the Medicines Australia Code of Conduct; Reform of the private health insurance regime; More rigorous IVD regime one step closer - but will it be trans-Tasman?; Labelling of complementary medicines; Meet the team; Australia's High Court grapples with the issue of obviousness again; Patenting enantiomers - court decides there is nothing sinister;]]></description><pubDate>Mon, 13 Aug 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200706/20/passage_of_anztpa_bill_in_new_zealand_unlikely.page</guid><title><![CDATA[Passage of ANZTPA Bill in New Zealand unlikely]]></title><link>http://www.claytonutz.com/publications/news/200706/20/passage_of_anztpa_bill_in_new_zealand_unlikely.page</link><description><![CDATA[A New Zealand Select Committee reported on 15 June 2007 that it could not recommend the passing of the Therapeutic Products and Medicines Bill. The Bill represents the implementing legislation for the regulation of therapeutic products in New Zealand, and gives effect to the Agreement between the Australian and New Zealand Governments for the Establishment of a Joint Scheme for the Regulation of Therapeutic Products.]]></description><pubDate>Wed, 20 Jun 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200706/18/pbs_reforms_introduced_to_parliament.page</guid><title><![CDATA[PBS reforms introduced to Parliament]]></title><link>http://www.claytonutz.com/publications/news/200706/18/pbs_reforms_introduced_to_parliament.page</link><description><![CDATA[The Government's plan to reform the Pharmaceutical Benefits Scheme ("PBS") has gained further momentum with the introduction of the National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007 into Federal Parliament on 24 May 2007.]]></description><pubDate>Mon, 18 Jun 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200705/04/draft_anztpa_bill-what_does_it_say.page</guid><title><![CDATA[Draft ANZTPA Bill - what does it say?]]></title><link>http://www.claytonutz.com/publications/news/200705/04/draft_anztpa_bill-what_does_it_say.page</link><description><![CDATA[As you would know, an exposure draft of the Therapeutic Products Bill 2007 ("Bill") governing the regulation of therapeutic products under the new Australia New Zealand Therapeutic Products Authority ("ANZTPA") was released for public consultation and comment on 2 April 2007. This is the first of a package of Bills to be released, to give effect to the Agreement between the Australian and New Zealand Governments for the Establishment of a Joint Scheme for the Regulation of Therapeutic Products ("the Agreement").]]></description><pubDate>Fri, 04 May 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20070402/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20070402/home.page</link><description><![CDATA[This issue includes: Update on ANZTPA - the Draft Advertising Rule; Latest news on the Therapeutic Products and Medicines Bill; Changes to the Good Manufacturing Practice clearance guidelines of overseas medicine manufacturers; Meet the Team; Defences to liability for defective products: Is there an international standard?; Quick dose; When does a product contain a pharmaceutical substance for the purposes of a patent extension?; Pharmaceutical patent term extensions - Full Federal Court defines "first regulatory approval date";]]></description><pubDate>Mon, 02 Apr 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20061201/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20061201/home.page</link><description><![CDATA[This issue includes: ANZTPA: Second phase of consultation is underway; Advertising Code 2006: Further steps towards a Trans-Tasman scheme; Meet the team: Dr Teresa Baker, Legal Co-ordinator - Pharmaceutical Regulatory Affairs, Sydney; Quick dose; The challenges of interlocutory injunctions: CSL Ltd v GlaxoSmithKline Australia; Wrongful life claims - recent decisions and further implications for the life sciences industry; Update on the TGN1412 trial: Review and recommendations of the Expert Scientific Group; The end of the rogue trader? Developments in UK consumer protection; Will springboarding changes have a significant impact on the Australian pharmaceutical industry?; Can a pharmaceutical patent term extension, once granted, be shortened or cancelled?; Pharmaceutical patent term extensions - eligibility, application deadline and length clarified;]]></description><pubDate>Fri, 01 Dec 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200609/04/cu_specialist_appointed_to_peak_government_review_body.page</guid><title><![CDATA[CU specialist appointed to peak government review body]]></title><link>http://www.claytonutz.com/publications/news/200609/04/cu_specialist_appointed_to_peak_government_review_body.page</link><description><![CDATA[Clayton Utz regulatory specialist Dr Teresa Baker has been appointed to the NSW division of the Administrative Appeals Tribunal effective 24 August. Federal Attorney-General Philip Ruddock announced Dr Baker as one of eight new appointees to the Tribunal, the body charged with reviewing decisions of Australian government departments and agencies. Dr Baker joins the Tribunal as a part-time member, joining four other NSW appointees.]]></description><pubDate>Mon, 04 Sep 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200608/29/international_comparative_legal_guide_to_pharmaceutical_advertising_2006.page</guid><title><![CDATA[International Comparative Legal Guide to: Pharmaceutical Advertising 2006]]></title><link>http://www.claytonutz.com/publications/news/200608/29/international_comparative_legal_guide_to_pharmaceutical_advertising_2006.page</link><description><![CDATA[Product liability law experts, Clayton Utz partner Colin Loveday and senior associate Greg Williams, have contributed the Australian chapter to the "International Comparative Legal Guide to: Pharmaceutical Advertising 2006". Contributions are by invitation only, and Colin and Greg are the only Australian lawyers featured.]]></description><pubDate>Tue, 29 Aug 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060731/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060731/home.page</link><description><![CDATA[This issue includes: STOP PRESS!; Consultation Forums on ANZTPA Held - Implications of the Joint Scheme for Industry; Quick dose - regulatory developments in Australia and overseas; Wrongful life claims - recent decisions and the implications for the life sciences industry; Conducting clinical trials with biological medicines - lessons learnt from the UK TGN1412 trial; Once weekly method of treatment not a patentable invention; Is an injunction restraining further infringement automatic when a patent is held infringed?; Patent quips: Edited by Wayne Condon;]]></description><pubDate>Mon, 31 Jul 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200605/30/a_strong_dose_of_regulation_for_pharmaceuticals_sector.page</guid><title><![CDATA[A strong dose of regulation for pharmaceuticals sector]]></title><link>http://www.claytonutz.com/publications/news/200605/30/a_strong_dose_of_regulation_for_pharmaceuticals_sector.page</link><description><![CDATA[Companies operating in the pharmaceuticals and medical devices sectors will need to be extra vigilant in maintaining good business and risk management practices following changes to the regulatory regime under which they operate, according to a leading corporate lawyer.]]></description><pubDate>Tue, 30 May 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200605/22/be_prepared_new_tga_enforcement_powers_start_soon.page</guid><title><![CDATA[Be prepared! New TGA enforcement powers start soon]]></title><link>http://www.claytonutz.com/publications/news/200605/22/be_prepared_new_tga_enforcement_powers_start_soon.page</link><description><![CDATA[Australia now has a strengthened regime within the Australian therapeutic goods market including a tiered regime of criminal offences and civil penalties, higher penalties, and liability for "executive officers", following the passage of the Therapeutic Goods Amendment Act 2006. Most of the changes will come into effect on 31 May 2006, breathing new life into the powers of the Therapeutic Goods Authority ("TGA") to enforce the Therapeutic Goods Act 1989 (Cth).]]></description><pubDate>Mon, 22 May 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060509/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060509/home.page</link><description><![CDATA[This issue includes: Australia New Zealand Therapeutic Products Authority - Full steam ahead; Quick dose; Tort law reform - The final chapter; The NHMRC Amendment Bill 2006 - greater autonomy and transparency; Can you patent a method of medical diagnosis or treatment?; Added protection for US method patents could restrict local research; The Omnitrope experience . Is it STOP or GO for follow-on biologicals in Australia?; Patent quips;]]></description><pubDate>Tue, 09 May 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060228/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060228/home.page</link><description><![CDATA[This issue includes:]]></description><pubDate>Tue, 28 Feb 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200512/20/therapeutic_goods_amendment_bills_delayed_until_next_year.page</guid><title><![CDATA[Therapeutic Goods Amendment Bills: Delayed until next year.]]></title><link>http://www.claytonutz.com/publications/news/200512/20/therapeutic_goods_amendment_bills_delayed_until_next_year.page</link><description><![CDATA[In its final parliamentary session this year, the Senate deferred voting on the Therapeutic Goods Amendment Bill 2005 and the Therapeutic Goods Amendment Bill (No.2) 2005. Both Bills remain at the second reading stage in the Senate and debate has been adjourned until 2006.]]></description><pubDate>Tue, 20 Dec 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20051206/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20051206/home.page</link><description><![CDATA[This issue includes: Transparency reforms to the Pharmaceutical Benefits Scheme introduced under the FTA; Food/therapeutic goods interface: Can apples be compared to orange pills?; Quick dose; 8  rules of comparative advertising; Code of best practice for reporting by life science companies; Is Australian law on patents and experimental use about to be clarified?;]]></description><pubDate>Tue, 06 Dec 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200510/05/clayton_utz_partner_joins_metabolic_board.page</guid><title><![CDATA[Clayton Utz partner joins Metabolic board]]></title><link>http://www.claytonutz.com/publications/news/200510/05/clayton_utz_partner_joins_metabolic_board.page</link><description><![CDATA[The appointment of Clayton Utz life sciences partner Robyn Baker to the board of Melbourne-based biotech Metabolic Pharmaceuticals Limited as a non-executive director confirms widespread recognition of Clayton Utz as the leading Australasian law firm in the life sciences sector.]]></description><pubDate>Wed, 05 Oct 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20050921/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20050921/home.page</link><description><![CDATA[This issue includes: The TGA gets set to get tough: Likely new enforcement options; Code 2005: The first Australian regulatory step towards a trans-Tasman scheme; Advertising prices of prescription products to be made clearer; Quick dose; Australian consumer product safety: fundamental reform not needed, just improvements; Health information privacy - Another layer of protection; If you dice the mice you must pay the price; The US Supreme Court decides an exceptional patent case;]]></description><pubDate>Wed, 21 Sep 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200508/29/a_strong_dose_of_regulation_set_to_shake_up_pharmaceuticals_sector.page</guid><title><![CDATA[A strong dose of regulation set to shake up pharmaceuticals sector]]></title><link>http://www.claytonutz.com/publications/news/200508/29/a_strong_dose_of_regulation_set_to_shake_up_pharmaceuticals_sector.page</link><description><![CDATA[Companies operating in the pharmaceuticals and medical devices sectors will be forced to review their business practices if proposed changes to the regulatory regime under which they operate are passed through Federal Parliament, according to a leading corporate lawyer.]]></description><pubDate>Mon, 29 Aug 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200508/26/a_possible_new_approach_to_funding_health_care.page</guid><title><![CDATA[A possible new approach to funding health care]]></title><link>http://www.claytonutz.com/publications/news/200508/26/a_possible_new_approach_to_funding_health_care.page</link><description><![CDATA[Australia is spending progressively more on health care. Over coming decades, increasing health costs will place the financial sustainability of the health system under growing pressure.]]></description><pubDate>Fri, 26 Aug 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200508/24/tga_gets_set_to_get_tough.page</guid><title><![CDATA[TGA gets set to get tough]]></title><link>http://www.claytonutz.com/publications/news/200508/24/tga_gets_set_to_get_tough.page</link><description><![CDATA[The Therapeutic Goods Amendment Bill 2005 ("the Bill") has just been tabled in the Federal Parliament. When enacted, the provisions will significantly expand the powers of the Therapeutic Goods Administration ("TGA") in the enforcement of the Therapeutic Goods Act ("the Act").]]></description><pubDate>Wed, 24 Aug 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20050715/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20050715/home.page</link><description><![CDATA[This issue includes: Government signals tighter regulation of complementary medicines; Clinical trials under the Microscope; Proposed new model for the scheduling of medicines and poisons; Quick dose; Deep vein thrombosis - an "accident" or just bad luck?; ACCC v Baxter Healthcare Pty Limited [2005] FCA 581; Oh my Lord! - The House of Lords clarifies UK patent law; Claim construction and fair basis considered; Extending the term of a pharmaceutical patent; The experimental use exception to patent infringement - a preview;]]></description><pubDate>Fri, 15 Jul 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200506/20/latest_on_web-based_access_to_prescription_medicines_information.page</guid><title><![CDATA[Latest on web-based access to prescription medicines information]]></title><link>http://www.claytonutz.com/publications/news/200506/20/latest_on_web-based_access_to_prescription_medicines_information.page</link><description><![CDATA[The Therapeutic Goods Administration recently engaged the services of mpconsulting to provide advice to the TGA on the most appropriate means for improving consumer and professional access to web-based copies of up-to-date Consumer Medicine Information ("CMI") and Product Information ("PI") documents.]]></description><pubDate>Mon, 20 Jun 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200505/12/tga_initial_discussion_paper-improving_access_to_prescription_medicines_information.page</guid><title><![CDATA[TGA Initial Discussion paper - Improving access to prescription medicines information]]></title><link>http://www.claytonutz.com/publications/news/200505/12/tga_initial_discussion_paper-improving_access_to_prescription_medicines_information.page</link><description><![CDATA[No doubt you are aware that the Therapeutic Goods Administration ("TGA") recently engaged the services of mpconsulting to provide advice to the TGA on the most appropriate means for improving consumer and professional access to web-based copies of up-to-date Consumer Medicine Information ("CMI") and Product Information ("PI") documents.]]></description><pubDate>Thu, 12 May 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200503/24/the_alrc_delivers_its_report_into_gene_patenting_and_human_health.page</guid><title><![CDATA[The ALRC Delivers its Report into Gene Patenting and Human Health]]></title><link>http://www.claytonutz.com/publications/news/200503/24/the_alrc_delivers_its_report_into_gene_patenting_and_human_health.page</link><description><![CDATA[After an 18 month inquiry, the Australian Law Reform Commission ("ALRC") has recently released its report into gene patenting and human health, Genes and Ingenuity: Gene Patenting and Human Health.]]></description><pubDate>Thu, 24 Mar 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200503/11/ramifications_for_pharmaceutical_and_biotech_patent_owners_of_the_us-australia_free_trade_agreement.page</guid><title><![CDATA[Ramifications for Pharmaceutical and Biotech Patent Owners of the US-Australia Free Trade Agreement]]></title><link>http://www.claytonutz.com/publications/news/200503/11/ramifications_for_pharmaceutical_and_biotech_patent_owners_of_the_us-australia_free_trade_agreement.page</link><description><![CDATA[The legislation implementing the Australia/US Free Trade Agreement ("FTA") came into force on 1 January 2005. The implementing legislation makes certain consequential amendments to Australia's Therapeutic Goods Act 1989 which establishes a regime designed to dissuade owners of suspect pharmaceutical patents from commencing patent infringement proceedings against alleged infringers.]]></description><pubDate>Fri, 11 Mar 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20041122/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20041122/home.page</link><description><![CDATA[This issue includes: Future regulation of cell and tissue therapies; ALRC report: gene patenting and human health; Proposed changes to medicine labelling requirements following the Pan recall; ASX paves the way for self-regulation of the biotech industry; International recognition for our Life Sciences team;]]></description><pubDate>Mon, 22 Nov 2004 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/docs/FTA_Article_Aug04.pdf</guid><title><![CDATA[The impact of the US FTA on the generic pharmaceutical industry & the PBS]]></title><link>http://www.claytonutz.com/docs/FTA_Article_Aug04.pdf</link><description><![CDATA[The Australia-US FTA was accompanied by media reports and public statements that it would cause the sky to fall on the PBS and Australian generics, but Nicholas Tyacke wonders if they were right.]]></description><pubDate>Tue, 31 Aug 2004 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200403/22/experimental_use_under_the_microscope.page</guid><title><![CDATA[Experimental use under the microscope]]></title><link>http://www.claytonutz.com/publications/news/200403/22/experimental_use_under_the_microscope.page</link><description><![CDATA[Should there be an express exemption in the Patents Act so that the experimental use of patented inventions is not an infringement of the patent?]]></description><pubDate>Mon, 22 Mar 2004 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200401/20/whos_a_sponsor_under_the_therapeutic_goods_act.page</guid><title><![CDATA[Who's a sponsor under the Therapeutic Goods Act?]]></title><link>http://www.claytonutz.com/publications/news/200401/20/whos_a_sponsor_under_the_therapeutic_goods_act.page</link><description><![CDATA[How many sponsors can a therapeutic good have? The recent decision of Hui v Lane [2003] SASC 401 (11 December 2003) states that there can be more than one sponsor at different points in time, raising questions about sponsors' responsibilities under the Therapeutic Goods Act 1989.]]></description><pubDate>Tue, 20 Jan 2004 00:00:00 EST</pubDate></item></channel></rss>